Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

gargoyl Jul. 11 at 3:16 PM

$BLRX about to break through $5.06 🦋 . . 🦍 👀

0 · Reply

gargoyl Jul. 11 at 2:12 PM

$BLRX the swath of MM have moved there base camp to 6.04 on the ask .. Watch , we break back into the mid and high fives

0 · Reply

gargoyl Jul. 11 at 3:03 AM

$BLRX 👀 4 of 4 Tomorrow 9:30AM watching with ☕️ coffee and French Vanilla She’s ready ….. $5.06 was tapped twice in two days in a row , volume was 55k both days .. Looking for volume push tomorrow over 5.50 pivot This year target 🎯 $12 maybe by August 30 2nd Qt ER Long the 🦋

0 · Reply

gargoyl Jul. 11 at 2:58 AM

$BLRX 👀 3 of 4 $SNY take look 🐥 peeps

0 · Reply

gargoyl Jul. 11 at 2:56 AM

$BLRX 👀 2 of 4 Something big is brewing.. tomorrow pop 💥 $BMY watch peeps 🐥

0 · Reply

gargoyl Jul. 11 at 2:54 AM

$BLRX 👀 1 of 4 BiolineRx is about to explode $REGN watch peeps 🐥

0 · Reply

TenaciousG34 Jul. 10 at 11:52 PM

$BLRX I think Q3 has some 🧨 for this one 👀

1 · Reply

JohnQpub Jul. 9 at 7:13 PM

$BLRX uh, nibble nibble This is feeling like a rip is in order....

0 · Reply

gargoyl Jul. 9 at 6:08 PM

$BLRX the wall is thin on bid all up to 5.54 , then everybrothers MM is got their hand out , maybe a little tussle there if we can double our volume on way out today , this is creeping me out in a good way

0 · Reply

gargoyl Jul. 9 at 5:53 PM

$BLRX Wow, 12% pop on only 54k shares, time 1:53 on a Wednesday July 9th, let it be recorded she’s going to blow through $5 like a yesterday Take heed Her comes my brother

0 · Reply

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 6 weeks ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 6 weeks ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 6 weeks ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 7 weeks ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 3 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 3 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 3 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 6 months ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 6 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 6 months ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 6 months ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 8 months ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 8 months ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 8 months ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 8 months ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 8 months ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 9 months ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 10 months ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 11 months ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 11 months ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 1 year ago

BioLineRx: Still A Buy, With Some Questions

Dec 2, 2023, 11:25 PM EST - 1 year ago

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

Nov 20, 2023, 1:54 PM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 13, 2023, 7:00 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Oct 31, 2023, 9:00 AM EDT - 1 year ago

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Oct 12, 2023, 7:00 AM EDT - 1 year ago

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

Sep 28, 2023, 7:00 AM EDT - 1 year ago

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

Sep 19, 2023, 7:00 AM EDT - 1 year ago

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

Sep 18, 2023, 1:28 AM EDT - 1 year ago

Assessing BioLineRx As A Buy After Drug Approval

gargoyl Jul. 11 at 3:16 PM

$BLRX about to break through $5.06 🦋 . . 🦍 👀

0 · Reply

gargoyl Jul. 11 at 2:12 PM

$BLRX the swath of MM have moved there base camp to 6.04 on the ask .. Watch , we break back into the mid and high fives

0 · Reply

gargoyl Jul. 11 at 3:03 AM

0 · Reply

gargoyl Jul. 11 at 2:58 AM

$BLRX 👀 3 of 4 $SNY take look 🐥 peeps

0 · Reply

gargoyl Jul. 11 at 2:56 AM

$BLRX 👀 2 of 4 Something big is brewing.. tomorrow pop 💥 $BMY watch peeps 🐥

0 · Reply

gargoyl Jul. 11 at 2:54 AM

$BLRX 👀 1 of 4 BiolineRx is about to explode $REGN watch peeps 🐥

0 · Reply

TenaciousG34 Jul. 10 at 11:52 PM

$BLRX I think Q3 has some 🧨 for this one 👀

1 · Reply

JohnQpub Jul. 9 at 7:13 PM

$BLRX uh, nibble nibble This is feeling like a rip is in order....

0 · Reply

gargoyl Jul. 9 at 6:08 PM

0 · Reply

gargoyl Jul. 9 at 5:53 PM

$BLRX Wow, 12% pop on only 54k shares, time 1:53 on a Wednesday July 9th, let it be recorded she’s going to blow through $5 like a yesterday Take heed Her comes my brother

0 · Reply

gargoyl Jul. 9 at 5:43 PM

$BLRX 👀 🦍 🦍 🦋 Peeps 🐥. @. $LABD $LABU

0 · Reply

quangfl Jul. 9 at 5:32 PM

$BLRX looking strong. Small cap so high risk but high reward. Chart looks great after some consolidation

0 · Reply

gargoyl Jul. 9 at 4:55 PM

$BLRX 👀 Beast mode 🦍 on deck Momentum is 👂 hear PDAC Let’s treat cancer ♋️ $BMY $RGEN $PFE

0 · Reply

gargoyl Jul. 9 at 4:34 PM

$BLRX when fortitude is stronger than diamonds fortunes follow , Phil 🥷🏿 rules not because of luck, but because he never stopped, his drive to heal people with new medicine and treatments is why we longs never left his side .. may 🙏 bless every struggling person with disease and cancer and may the wind always be at your back Phil. longest the 🦋

0 · Reply

gargoyl Jul. 9 at 3:12 PM

$BLRX 👀 runner ?? 🏃‍♀️ 🩳 * * * 🔫 Percolating $BMY $VSTM @ peeps at $BLUE

0 · Reply

gargoyl Jul. 9 at 3:00 PM

$BLRX longs who know where we have been see the future as bright here. The company foundation given Phil’s tireless pursuit of changing lives has not only strengthened the balance sheet but provides powerful catalyst 🐈‍⬛ for surprise growth not to mention PDAC advances in trials with esteemed partnerships and collaborations. The website is available for DD. The chart now has reached a perfect storm momentum on trend and pivots to warrant close attention to a breakout . $XBI $REGN Longest the 🦋

0 · Reply

JL_TradeZ Jul. 9 at 10:22 AM

$BLRX has a tight coil forming under $4.45 with a 4.24M float and recent ASCO 2025 data confirmation for its lead drug Motixafortide in first-line pancreatic cancer. H.C. Wainwright reiterated a Buy on July 2 after the results. No active dilution on file since April, and the chart is sitting right on VWAP with thin asks at $4.64 and $4.68. If it breaks $4.45 on volume, this could ignite fast Targets: 4.80 / 5.10 / 5.65 Stop: 4.05

0 · Reply

Future18 Jul. 8 at 8:25 PM

$BLRX I appreciate Twongstocks posts very much. They are informative and fact based and include sources. They give the kind of information I would think those interested in this stock should know and really ought to be getting ourselves. So very appreciated.

1 · Reply

TwongStocks Jul. 8 at 2:19 PM

$BLRX Washington University updated the status for the trial testing motixafortide + natalizumab as a stem cell mobilizer for sickle cell patients. The status is now COMPLETE. https://clinicaltrials.gov/study/NCT05618301 The rights to SCD now belong to Ayrmid/Gamida. Per the agreement, trial completion will not trigger a milestone payment. No milestone payments in SCD until sales begin (screenshot). In BLRX's previous earnings filing, it stated that final data is due in 2025 (screenshot). If the researchers at WashU plan to present the final data at a medical conference, my guess is at this year's ASH in December. The initial proof of concept data was presented at ASH in 2024. Abstracts for this year's ASH are due by Aug 5, with late-breaking abstract submissions due in Oct.

0 · Reply

Future18 Jul. 8 at 11:05 AM

$BLRX I haven’t seen anything since July 1. Is this chat still working?

1 · Reply

gargoyl Jul. 7 at 1:20 PM

$BLRX good morning 🌞 The stars ⭐️ are aligned, everything is as it should be , framed w/ ☕️ coffee with French vanilla ✌️ Let the journey begin.. long the 🦋

0 · Reply

gargoyl Jul. 2 at 11:19 PM

$BLRX 👀 heading back to $5 Thursday then 3 day weekend , watching, averaging in … $REGN $BMY Long the 🦋

0 · Reply

Market Cap	20.04M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	61.00
Profit Margin	-31.86%
Debt to Equity Ratio	0.59

Volume	41,400
Avg Vol	849,890
Day's Range	N/A - N/A
Shares Out	4.26M
Stochastic %K	64%
Beta	1.25
Analysts	Strong Sell
Price Target	$26.00